Clinical Trial Update: Antiremodeling Effect Of Aldosterone Receptors Blockade With Canrenone In Mild Chronic Heart Failure. AREA IN-CHF Study [Phase 3]

View source ↗

Summary

Phase 3 trial update on canrenone (aldosterone receptor blocker) for mild chronic heart failure shows results from the AREA IN-CHF study.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure

Drugs mentioned

• Canrenone (canrenone)

Snippet

Sponsor: Heart Care Foundation | Conditions: Heart Failure | Phase 3 | Status: COMPLETED